Arrowhead Pharmaceuticals (NASDAQ:ARWR) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) from a hold rating to a strong sell rating in a research note issued to investors on Saturday,Wall Street Zen reports.

Other research analysts have also issued research reports about the stock. Chardan Capital reaffirmed a “buy” rating and set a $115.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Thursday, October 15th. UBS Group initiated coverage on Arrowhead Pharmaceuticals in a research report on Thursday, October 15th. They set a “buy” rating and a $109.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 17th. Royal Bank Of Canada restated an “outperform” rating and set a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Friday. Finally, B. Riley Financial upped their price target on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a report on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $98.93.

View Our Latest Stock Report on Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR opened at $44.21 on Friday. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90. Arrowhead Pharmaceuticals has a one year low of $37.06 and a one year high of $95.49. The company has a fifty day moving average price of $62.48 and a 200 day moving average price of $70.90. The stock has a market cap of $6.23 billion, a P/E ratio of -8.65 and a beta of 1.34.

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The biotechnology company reported ($3.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.52) by ($1.48). The company had revenue of $37.79 million during the quarter, compared to analyst estimates of $61.18 million. Arrowhead Pharmaceuticals had a negative return on equity of 133.48% and a negative net margin of 160.64%. The business’s revenue for the quarter was down 45.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.01) earnings per share. Analysts anticipate that Arrowhead Pharmaceuticals will post -4.73 earnings per share for the current year.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Versant Capital Management Inc raised its stake in shares of Arrowhead Pharmaceuticals by 285.1% in the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 248 shares in the last quarter. Carolina Wealth Advisors LLC boosted its position in shares of Arrowhead Pharmaceuticals by 80.6% during the 2nd quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 154 shares in the last quarter. Optiver Holding B.V. boosted its position in shares of Arrowhead Pharmaceuticals by 83.8% during the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 186 shares in the last quarter. Persistent Asset Partners Ltd bought a new stake in Arrowhead Pharmaceuticals in the second quarter valued at about $39,000. Finally, Allied Private Wealth LLC bought a new stake in Arrowhead Pharmaceuticals in the second quarter valued at about $43,000. Institutional investors own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

(Get Free Report)

Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues. The company’s research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.

Further Reading

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.